Search

Displaying results 3171 - 3180 of 10000 in total
  1. Drug

    Flurpiridaz F-18

    go.drugbank.com/drugs/DB18773
    Approved

    [A264519] Flurpiridaz F-18 is an analog of pyridaben, a mitochondrial complex 1 (MC-1) inhibitor.[L51659] … Flurpiridaz F-18 is a radioactive diagnostic drug indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI), which is an imaging process used in patients with known or suspected

  2. Drug

    Revakinagene taroretcel

    go.drugbank.com/drugs/DB05344
    ApprovedInvestigational

    [A265115] On March 6, 2025, FDA approved revakinagene taroretcel for the treatment of idiopathic macular telangiectasia type 2. … [L52270] Revakinagene taroretcel delivers CNTF to the retina to lower the extent of neuroregeneration.

  3. Drug

    Tragacanth

    go.drugbank.com/drugs/DB10667
    Approved

    Tragacanth allergenic extract is used in allergenic testing.

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Faricimab

    go.drugbank.com/drugs/DB15303
    ApprovedInvestigational

    [L43085] On April 9, 2026, the FDA approved an updated label that extended faricimab treatment for macular edema following retinal vein occlusion (RVO) beyond six months.[L40026] … [A225985, A225990, A225995, A226000, A226005, A226010] Faricimab was approved by the FDA on January 28, 2022, and is currently marketed under the trademark VABYSMO by Genentech, Inc.

  5. Drug

    Ciclesonide

    go.drugbank.com/drugs/DB01410
    ApprovedInvestigational

    Ciclesonide is a glucocorticoid used to treat obstructive airway diseases. It is marketed under the brand name Alvesco.

    Products: ALVESCO 160 UG 120 HUB, FINORINEX® SPRAY NASAL 50 µG
  6. Drug

    Salmon calcitonin

    go.drugbank.com/drugs/DB00017
    ApprovedInvestigational

    Synthetic peptide, 32 residues long formulated as a nasal spray.

  7. Drug

    Eladocagene exuparvovec

    go.drugbank.com/drugs/DB16780
    ApprovedInvestigational

    By promoting the expression of AADC, eladocagene exuparvovec leads to the development of motor function in patients with AADC deficiency. … [A253697,L43672] Before the approval of this gene therapy, the treatment options for patients with AADC deficiency were limited to attempts to increase monoamine neurotransmitter production, decrease neurotransmitter

  8. Drug

    Peach

    go.drugbank.com/drugs/DB10552
    Approved

    Peach allergenic extract is used in allergenic testing.

  9. Drug

    Blonanserin

    go.drugbank.com/drugs/DB09223
    Investigational

    As a second-generation (atypical) antipsychotic, it is significantly more efficacious in the treatment of the negative symptoms of schizophrenia compared to first-generation (typical) antipsychotics. … It offers improved tolerability as it lacks side effects such as extrapyramidal symptoms, excessive sedation, or hypotension.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  10. Drug

    Vasopressin

    go.drugbank.com/drugs/DB00067
    ApprovedInvestigational

    [A228008, A228013, A228018, L31413] The vasopressive effect of posterior pituitary gland extracts was noted in 1895, while vasopressin itself was not purified until 1951. … Vasopressin (arginine-vasopressin or antidiuretic hormone) is a nonapeptide primarily produced in the hypothalamus that exhibits diverse physiological functions related to diuresis, hemodynamic modulation